Latigo Biotherapeutics Inc. (LTGO)
LTGO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | LTGO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0002056611 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Accordingly, the prior substantial doubt about the Company's ability to continue as a going concern has been alleviated. 2." | 10-Q 2026-11-05 |
| Cash and burn | $401.2M cash; operating cash flow -$19.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 66,299,347 (2026-11-02). | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Diego, California, United States | PCAOB Form AP 2026-08-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $2.5M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$20.9M | -$19.5M | $401.2M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q3 2026 2026-06-30 | Not filed | -$25.8M | Not filed | $55.0M | $64.9M | Needs four quarters | 10-Q 2026-11-05 |
| Q3 2026 2026-03-31 | Not filed | -$23.0M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q3 2026 2025-09-30 | Not filed | -$24.8M | -$19.9M | $104.6M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q3 2026 2025-06-30 | Not filed | -$25.8M | Not filed | $74.5M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q3 2026 2025-03-31 | Not filed | -$21.0M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-08-07 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
Source: SEC EDGAR submissions feed, 46 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.0% |
| 1 month | -16.5% |
| 3 months | -34.6% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -47.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RIGL | Rigel Pharmaceuticals Inc. | $43.73 | -1.64% | $823.4M |
| SNDX | Syndax Pharmaceuticals Inc. | $9.13 | -3.39% | $821.6M |
| CTY | City Therapeutics Inc. | $16.98 | -6.19% | $854.6M |
| IRWD | Ironwood Pharmaceuticals Inc. | $4.85 | +0.41% | $802.9M |
| COLL | Collegium Pharmaceutical Inc. | $25.43 | +0.43% | $790.2M |
| PHAR | Pharming Group N.V. ADS each representing 10 | $12.59 | -0.08% | $889.2M |
| IVA | Inventiva S.A. American Depository Shares | $3.32 | -9.78% | $784.5M |
| CRVS | Corvus Pharmaceuticals Inc. | $10.60 | -0.38% | $894.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier